Orthopedic Surgery, Sports Medicine · Sedalia, MO
NPI
1487623260
Since 2006
Specialty
Orthopedic Surgery, Sports Medicine
Code 207XX0005X
Group practices
1
Medicare group memberships
Hospitals
1
Hospital affiliations
2301 S Ingram Ave
Sedalia, MO, 65301
Phone (660) 826-5890
Groups this clinician bills Medicare through
Medicare paid, 2024
$288K
15,886 services
Medicare patients, 2024
595
Average age 75
Drug cost, 2024
$23K
2,362 prescriptions
Company payments, 2025
$71.44
From 1 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Douglas W Kiburz was code J1010 (injection, methylprednisolone acetate, 1 mg), 7,320 times for 78 patients. In total Douglas W Kiburz billed 15,886 services in 111 codes, and Medicare paid $288K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2016-03-15.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J1010 Injection, methylprednisolone acetate, 1 mg | Office | 7,320 | 78 | $0.09 | $692 |
| J3304 Injection, triamcinolone acetonide, preservative-free, extended-release, microsphere formulation, 1 mg | Office | 4,096 | 76 | $13.71 | $56K |
| J0702 Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg | Office | 1,875 | 152 | $4.87 | $9,131 |
| 99213 Office E&M - Established | Office | 364 | 266 | $59.48 | $22K |
| 20610 Joint Injection | Office | 313 | 226 | $42.86 | $13K |
| 99214 Office E&M - Established | Office | 214 | 168 | $77.85 | $17K |
| 73560 X-ray - Lower Extremity | Office | 179 | 125 | $19.14 | $3,426 |
| 99212 Office E&M - Established | Office | 112 | 98 | $35.71 | $4,000 |
| 72100 X-ray - Spine and Pelvis | Office | 74 | 72 | $23.34 | $1,727 |
| 73030 X-ray - Upper Extremity | Office | 65 | 54 | $20.85 | $1,355 |
| 64624 Musculoskeletal | Facility | 55 | 55 | $122.56 | $6,741 |
| 27447 Arthroplasty - Knee | Facility | 53 | 51 | $920.43 | $49K |
| 99203 Office E&M - New | Office | 45 | 45 | $61.07 | $2,748 |
| 73130 X-ray - Upper Extremity | Office | 40 | 26 | $25.04 | $1,002 |
| 64721 Musculoskeletal | Facility | 33 | 27 | $295.41 | $9,748 |
By year: 2022 $307K for 8,183 services; 2023 $324K for 9,575 services; 2024 $288K for 15,886 services.
Medicare prescription drug claims, 2024
In 2024, the drug Douglas W Kiburz prescribed most often to Medicare patients was Meloxicam, with 463 prescriptions and refills. In total Douglas W Kiburz wrote 2,362 Medicare prescriptions that cost $23K.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Meloxicam Generic | 463 | 947 | 151 | $1,736 |
| Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen | 433 | 433 | 254 | $5,738 |
| Celecoxib Generic | 236 | 296 | 133 | $4,689 |
| Gabapentin Generic | 215 | 388 | 72 | $1,779 |
| Cephalexin Generic | 185 | 187 | 95 | $487 |
| Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen | 154 | 154 | 80 | $1,724 |
| Tranexamic Acid Generic | 126 | 126 | 117 | $1,553 |
| Methylprednisolone Generic | 95 | 95 | 78 | $723 |
| Ibuprofen Generic | 73 | 105 | 25 | $731 |
| Tramadol Hcl Generic | 50 | 50 | 33 | $206 |
| M-Natal Plus Pnv,calcium 72/Iron/Folic Acid | 37 | 102 | 34 | $452 |
| Nortriptyline Hcl Generic | 32 | 46 | 12 | $246 |
| Prenatal Vitamin Plus Low Iron Pnv,calcium 72/Iron/Folic Acid | 28 | 89 | 27 | $649 |
| Cyclobenzaprine Hcl Generic | 24 | 24 | 17 | $137 |
| Sulfamethoxazole-Trimethoprim Sulfamethoxazole/Trimethoprim | 23 | 24 | 20 | $99.79 |
Brand drugs: 91 claims; generic drugs: 2,185 claims; opioid claims: 652.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Douglas W Kiburz $71.44 ($71.44 in general payments such as food, travel and fees) from 1 company. The largest payer was Acumed LLC with $71.44.
| Company | Payments | Amount |
|---|---|---|
| Acumed LLC | 2 | $71.44 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.